Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17448589 | 0.82 | CES2 (0.39) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL383565 | 0.78 | CES2 (0.44) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL440959 | 0.76 | CES2 (0.58) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL15329899 | 0.76 | CES2 (0.42) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL16823330 | 0.76 | CES2 (0.42) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL10271930 | 0.76 | CES2 (0.42) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL16861287 | 0.76 | CES2 (0.42) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL19998396 | 0.76 | GABRA1 (0.48) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL2550800 | 0.75 | CES2 (0.38) | CES2MAPTIDO1RAPGEF4XPO1 | |
| SCHEMBL2879502 | 0.74 | CES2 (0.41) | CES2MAPTIDO1RAPGEF4XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011089985-A1 | COSMETIC COMPOSITION FOR KERATIN FIBERS | L'OREAL (FR) | 2011-07-28 | — | — | WO | disclosed |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| WO-2007037995-A2 | EXTRACTION AGENT AND METHOD FOR FORMING AN EXTRACTION AGENT FOR THE SEPARATION OF ACTINIDES FROM LANTHANIDES | BATTELLE ENERGY ALLIANCE, LLC (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | PNISR, PRMT9, PRMT8 | CES2 4435/4885MAPT 4425/4885IDO1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.